| Autor: |
Burnett-Bowie, Sherri-Ann M., Roupenian, Kristen C., Dere, Melissa E., Hang Lee, Leder, Benjamin Z. |
| Předmět: |
|
| Zdroj: |
Clinical Endocrinology; Jan2009, Vol. 70 Issue 1, p116-123, 8p, 1 Diagram, 1 Chart, 3 Graphs |
| Abstrakt: |
Objective To assess the effects of sustained aromatase inhibition in older hypogonadal men. Design and patients In a 1-year randomized, double-blind, placebo-controlled trial, 88 men, aged 60 years and older with testosterone levels between 5·2 and 10·4 nmol/l on a single measure or between 10·4 and 12·1 nmol/l on two consecutive measures, and with symptoms of hypogonadism were recruited. Subjects received either anastrozole 1 mg daily or placebo. Measurements Changes in gonadal steroid hormone levels, body composition [by computerized tomography (CT) and dual X-ray absorptiometry (DXA)], strength, prostate specific antigen (PSA), symptoms of benign prostatic hypertrophy (BPH), haematocrit and lipid levels were assessed. Results Testosterone levels increased from 11·2 ± 3·3 nmol/l at baseline to 18·2 ± 4·8 nmol/l at month 3 ( P < 0·0001 vs. placebo) while bioavailable testosterone levels increased from 2·7 ± 0·8 nmol/l at baseline to 5·4 ± 1·7 nmol/l at month 3 ( P < 0·0001 vs. placebo). Testosterone and biotestosterone levels peaked at month 3 and then declined by month 12 (though they remained significantly higher than baseline and greater than placebo). E2 levels decreased from 55·8 ± 15·4 pmol/l at baseline to 42·2 ± 13·6 pmol/l at month 3 and then remained stable ( P < 0·0001). Body composition and strength did not change, nor did PSA, BPH symptoms, haematocrit or lipid levels. Conclusions Anastrozole administration normalized androgen production in older hypogonadal men and decreased E2 production modestly. These alterations did not improve body composition or strength. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text